ReNeuron Group PLC's (LON:RENE) Michael Hunt caught up with Proactive London's Andrew Scott soon after the firm announced that its cell therapy for a degenerative eye disease held onto sight improvements for as long as a year after treatment.
The 12-month data reveal that people receiving surgery and the ReNeuron therapy could read seven more letters on a standard eye chart than those receiving surgery alone.
